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Abstract: 
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide, with a 5-
year survival rate of less than 5 percent.  Given the current lack of effective therapeutic options, 
novel strategies for treatment of this disease are urgently required.  Most PDAC tumors acquire 
mutations that result in constitutive activation of the GTPase KRAS, which promotes mitogen-
activated protein kinase (MAPK) signaling and tumor development.  Notably, KRAS-driven 
PDACs often exhibit increased dependence on autophagy, the process by which cells degrade 
internal components to mobilize energy stores.  When faced with cellular stress, such as nutrient 
or growth factor deprivation, tumor growth may initially slow in response to decreasing supplies 
of growth factors and cytokines.  Under these conditions, the induction of autophagy can enable 
continued tumor growth even in the presence of nutrient stress, and PDAC cells have been 
demonstrated to upregulate autophagy to maintain pro-tumorigenic growth.  Therefore, we posited 
that nutrient restriction in combination with autophagy inhibition would synergistically disrupt 
aberrant metabolic pathways and more effectively stunt PDAC tumor progression.  To determine 
the impact of transient autophagy inhibition, the aminoquinoline chloroquine (CQ, the only FDA-
approved autophagy inhibitor) was selected.  The combination of CQ and nutrient stress elicited a 
compounding effect on cellular proliferation in both murine and human-derived PDAC cells in 
vitro, demonstrating the potential efficacy of CQ and nutrient stress as an adjuvant therapy for 
PDAC.  Next, the mechanistic impact of permanent autophagy inhibition was explored, in order 
to identify secondary metabolic alterations arising in response to autophagy ablation.  Using 
CRISPR/Cas9 technology, a key gene in autophagic induction, autophagy related 5 (Atg5) was 
deleted in a murine-derived KRAS-mutant PDAC cell line (Panc02) rendering them autophagy-
deficient (Atg5-/-) PDAC cell line.  To understand the effect of systemic nutrient deprivation and 
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autophagy deficiency, these Atg5 wildtype and knockout cells were used in an in vivo model in 
which animals were prescribed a control or calorie restricted diet.  Upon intrapancreatic injection 
in a syngeneic C57BL/6 model, the complete loss of autophagy in Atg-/- cells resulted in reduced 
tumor growth relative to control (Atg5+/+) cells.  However, no differences in growth were observed 
in vitro under standard growth conditions or in combination with nutrient stress, indicating the 
cells with permanent autophagy deficiency have reprogrammed to grow in an autophagy-
independent manner.  Thus, our findings reveal a potential synergism between autophagy 
inhibition and nutrient stress, and also caution against suppressing autophagy completely and/or 
permanently due to the potential for pro-survival cellular adaptation to occur. 
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Introduction: 
Pancreatic Cancer Prevalence and Mortality 
Pancreatic cancer is one of the deadliest malignancies worldwide, with a 5-year survival 
rate less than 5 percent (Siegel, Miller et al. 2018).  In the United States, pancreatic cancer is 
currently the 4th most fatal cancer for both men and women, and is expected to become the 2nd 
leading cause of cancer-related deaths within the next decade (Rahib, Smith et al. 2014, Siegel, 
Miller et al. 2017).  Pancreatic ductal adenocarcinoma (PDAC) is the most common type of 
pancreatic cancer (Kleeff, Korc et al. 2016).  While little is known about the etiology of pancreatic 
cancer, novel strategies for treatment of PDAC are urgently needed.  The vast majority of PDAC 
tumors have an oncogenic activation of the GTPase KRAS, which promotes mitogen-activated 
protein kinase (MAPK) signaling and tumor development (Min-Jung Kim 2011).  Notably, 
autophagy, an intracellular catabolic process that disassembles cellular components to provide 
energy and nutrients to cells, is often heightened in KRAS-driven PDAC (Min-Jung Kim 2011).  
Thus, the process of autophagy has emerged as a potential therapeutic target for PDAC. 
Autophagy  
Autophagy is a highly conserved process that degrades and recycles cellular organelles and 
other cytoplasmic components (Kuma and Mizushima 2010, Ohsumi 2014).  While there are 
multiple autophagic pathways, including microautophagy and chaperone-mediated autophagy, in 
this thesis the term autophagy refers to a process also known as macroautophagy, wherein an 
isolation membrane, or phagophore, sequesters protein aggregates or organelles into 
autophagosomes for transport to the lysosomes for degradation (Mizushima, Yamamoto et al. 
2004, Kuma and Mizushima 2010, Mizushima and Levine 2010).  Thus autophagy is a key 
homeostatic process, removing redundant or damaged organelles, thereby generating metabolites 
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used to provide energy or create new macromolecules (Boya, Reggiori et al. 2013).  Autophagy is 
predominately regulated via the phosphoinositol 3-kinase/mammalian target of rapamycin 
complex I (PI3K/ mTORC1) pathway, a major orchestrator of cellular nutrient and energy balance 
(Jung, Ro et al. 2010, Saxton and Sabatini 2017).  When energy stores are high, mTORC1 
negatively regulates autophagy; however, under conditions of nutrient stress or starvation 
mTORC1 activity declines, leading to the induction of autophagy above basal levels (Levine and 
Kroemer 2008, Efeyan and Sabatini 2010, Jung, Ro et al. 2010). 
Autophagy and Cancer 
Autophagy has a complex role in cancer, as its effects appear to vary during different stages of 
cancer progression (White 2015).  In the context of carcinogenesis, autophagy is thought to exert 
protective effects, eliminating misfolded proteins and damaged cellular components.  Defects in 
autophagy can result in metabolic disruption, increased misfolded protein burden, the generation 
of reactive oxygen species (ROS), and subsequent oxidative stress (Komatsu, Waguri et al. 2007, 
Mathew, Karp et al. 2009, Mizushima and Komatsu 2011).  In untransformed cells, autophagy 
thereby serves a central role in mitigating stress and preserving genomic stability (Qu, Yu et al. 
2003).      
Conversely, in established tumors, autophagy may act as an essential adaptive response to 
overcome cellular stressors and promote tumor progression (White 2015), thus revealing 
autophagy as a “double edged-sword” in cancer (Huo, Cai et al. 2013).  Indeed, autophagy is 
instrumental in generating metabolic fuels for tumors limited by dysfunctional vascularization, and 
hypoxic or nutrient deficient microenvironments, and thus plays a role in the progression of cancer 
towards metastatic disease. (Dewhirst, Cao et al. 2008, Zhang, Bosch-Marce et al. 2008, White 
2015). 
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Metastatic disease is the primary cause of cancer related deaths (Weigelt, Peterse et al. 2005, 
Mehlen and Puisieux 2006, 2018).  Importantly, the majority of PDAC cases are diagnosed in late 
stages of the disease, having spread beyond the confines of the pancreas (Siegel, Miller et al. 2018).  
Therefore, an improved understanding of autophagy’s role in the biology of metastasis may offer 
novel therapeutic targets for PDAC (Thiery, Acloque et al. 2009).  The epithelial-to-mesenchymal 
transition (EMT) is a de-differentiation process whereby epithelial cells lose their polarity and 
assume the more motile, invasive phenotype of mesenchymal cells (Lock and Debnath 2008, 
Guadamillas, Cerezo et al. 2011).  In carcinoma cells, EMT elevates cancer cell presence in 
systemic circulation, thus increasing the likelihood of secondary tumor formation (Thiery, Acloque 
et al. 2009).     
Autophagy Inhibition and Therapy 
The “double-edged sword” of autophagy in cancer biology complicates the implications of 
targeting autophagy in cancer cells.  Early studies investigating the mechanism of autophagy 
utilized genetic silencing of key autophagy genes such as Atg5, Atg7, Atg12, and Becn1, effectively 
disrupting the autophagy process to provide more insight into the molecular role of each autophagy 
related gene (Pattison, Osinska et al. 2011, Cufi, Vazquez-Martin et al. 2012, Kim, Jeong et al. 
2012, Huo, Cai et al. 2013).  Despite gaps in the current understanding of autophagy’s complete 
role in cancer, these studies wherein autophagy is permanently disrupted in cancer cells support 
that inhibition of autophagy impairs tumor formation (White 2015, Lashinger, O’Flanagan et al. 
2016).   
Transient pharmacological inhibition of autophagy has been investigated for potential use as 
adjuvant therapy (Solomon and Lee 2009, Amaravadi, Lippincott-Schwartz et al. 2011, Long, 
Yang et al. 2013, Rainsford, Parke et al. 2015).  Many of these studies employ chloroquine (CQ), 
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a known pharmacologic inhibitor of autophagy.  CQ inhibits autophagy by preventing endosomal 
acidification, resulting in inhibition of lysosomal enzymes that require an acidic pH, and thus 
disrupting the maturation of the autophagolysosome (Solomon and Lee 2009, Amaravadi, 
Lippincott-Schwartz et al. 2011, Long, Yang et al. 2013, Rainsford, Parke et al. 2015).  A Phase 
II pharmacodynamic study in patients with metastatic PDAC showed no significant effect in 
progression-free survival in response to a CQ derivative (Wolpin, Rubinson et al. 2014).  However, 
in preclinical models of KRAS-driven pancreatic cancers, CQ has been shown to moderately 
reduce cell growth, tumorigenicity, and oxidative phosphorylation (Yang, Wang et al. 2011).    
  For the studies herein, we hypothesized that inhibition of autophagy under conditions in 
which autophagy dependence is increased – i.e., nutrient deprivation – would synergistically stunt 
PDAC tumor progression.  Calorie restriction (CR) is a dietary manipulation which decreases 
caloric intake without incurring malnutrition, and also induces autophagy (Mitchell, Tang et al. 
2015).  CR has been shown to effectively reduce tumor burden in various types of cancer 
(Brandhorst, Wei et al. 2013, Champ, Baserga et al. 2013, Di Biase, Lee et al. 2016, O'Flanagan, 
Smith et al. 2017, Rossi, Dunlap et al. 2017).  While CQ has worked to decrease tumor burden in 
preclinical models, treatment with transient autophagy inhibition may incur resistance to therapies 
that inhibit autophagy.  We hypothesize that cells may upregulate compensatory pathways to 
sustain cell proliferation under conditions of chronic autophagy inhibition.  Understanding the 
differences between transient, chronic, and permanent autophagy inhibition may allow for more 
effective treatment.  This body of work analyzes pharmacological, transient and chronic inhibition 
compared to permanent, genetic autophagy deficiency in combination with nutrient stress in in 
vitro and in vivo models. 
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Methods: 
Cell Culture 
All cell culture experiments used Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS), and 5mg/mL penicillin/streptomycin unless 
otherwise noted. 
Western Immunoblots 
Cells were lysed with radioimmunoprecipitation (RIPA) buffer supplemented with 
protease inhibiter (Roche) and Halt Phosphatase inhibitor (Thermo Scientific).  Protein 
concentration was determined via Bradford Assay using a Bradford protein quantification reagent 
(Biorad).  Forty micrograms of protein were loaded into a 4–15% stain-free gel (Biorad) and 
transferred onto a PVDF membrane using a Transblot Turbo transfer unit (Biorad).  Membranes 
were blocked with 5% bovine serum albumin (BSA) in Tris Buffered Saline containing 0.1% 
Tween (TBST) for 1 hour.  Membranes were then incubated with a primary antibody [LC3B I&II 
(Cell Signaling Technology, #3868S, Lot 13) (1:1000); b-Actin (Cell Signaling Technology, 
#4970L, Lot 14) (1:1000); Atg5 (Cell Signaling Technology, #12994S, Lot 3) (1:1000); PCNA 
(Cell Signaling Technology, #2586S) (1:1000); E-cadherin (BD Transduction Laboratories, 
#610181, Lot 4337639); N-cadherin (BD Transduction Laboratories, #4330954, Lot 4330954); 
Snail (Abcam, ab180714, Lot GR206562-1)] overnight at 4°C, followed by HRP-conjugated 
secondary antibodies raised against rabbit or mouse IgG (Sigma Aldrich).  Proteins were visualized 
using a Chemi Doc MP system (Biorad) and blots were quantified using ImageJ software. 
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Mechanistic (Pharmacologic) Inhibition of Autophagy 
CQ (Chloroquine Diphosphate Salt, Sigma #101352441) was dissolved in sterile, 
deionized H2O to make a 10 mM stock that was aliquoted (100 µL) and frozen at -20°C.  Wildtype 
mouse-derived Panc02 K-Ras driven pancreatic and wildtype human derived MIA PaCa-2 
pancreatic cancer cell lines were treated with or without a therapeutic dose of 10 µM CQ for 48 
hours for all experiments (Lashinger, O’Flanagan et al. 2016).  Western Immunoblots were used 
to determine the extent to which autophagy was successfully inhibited.     
Cell Proliferation 
An MTT assay was used to measure cell proliferation over a 48-hour period.  Panc02 and 
MIA PaCa-2 cells were seeded in a 96-well plate (5 x 103 cells/well). After 48 hours with or 
without CQ treatment, cells were stained with a solution containing 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (0.5 mg/mL) (MTT, M2128 SIGMA) for 1 hour.  Media 
was then aspirated, and cells were lysed with dimethyl sulfoxide (DMSO) to solubilize formazan 
crystals.  Absorbance was measured at 570 and 690 nm using UV-Vis spectroscopy via the 
Cytation 5 Cell Imaging reader (BioTek).  
Long Term Survival 
Long term growth and clonogenicity was measured using a colony formation assay.  
Panc02 and MIA PaCa-2 cells were seeded in 6-well plates (1 x 103 cells/well).  Cell culture media 
was replaced every 4 days.  After 2 weeks, the resulting colonies were fixed in 1 mL of 100% 
methanol for 5 minutes and then stained with 5% crystal violet (CV) in 100% methanol for 30 
minutes.  Plates were rinsed with water, and stained colonies were counted manually. 
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Exogenous Stress 
All cell culture experiments used DMEM and the following conditions were used to 
modulate nutrient stress in vitro: 
Table 1. Nutrient-stress media recipes 
 Control Serum Restriction Glucose Restriction 
FBS  10% 1% 10% 
Glucose 25 mM 25 mM 1 mM 
 
Genetic Inhibition of Autophagy: Generation of Atg5 Knockout Cells  
To genetically inhibit autophagy, CRISPR/Cas9 technology was used to cleave the gene 
encoding autophagy protein 5 (Atg5, Atg5) from the genome of murine Panc02 cells (Doudna and 
Charpentier 2014).  A lentiviral vector (Sigma-Aldrich) containing genes for both puromycin 
resistance and green fluorescent protein (GFP) expression was used to transduce the Panc02 cells.  
Following transduction, cells were selected by culturing in media with puromycin (5 ng/µL).  
Clonal cell populations were generated by screening for GFP positive single cells.  
qPCR was used to confirm the absence of the DNA sequence in the genome.  Lack of Atg5 
expression was confirmed through western immunoblotting.  
Growth Dynamics 
Growth curves were generated by culturing cells under puromycin selection over a 96-hour 
period.  Panc02 Atg5+/+ and Atg5-/- cells were seeded in a 24-well plate (4 x 103 cells/well) and 
cell numbers were analyzed at hours 24, 48, 72, and 96.  Cells were trypsinized, stained with trypan 
blue for live/dead discrimination, and live cells were counted using a hemocytometer.    
Three dimensional clonogenic growth was measured using an agarose-based assay.  
Agarose (0.1%, 2mL) was added to each well of a 6-well dish and left for 30 minutes to solidify.  
Atg5+/+ and Atg5-/- cells (1.0 x 105) were suspended in agarose (0.1%, 7 mL) and culture media (7 
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mL), and this suspension (2 mL) was added to each well and left to solidify for 30 min.  A layer 
of culture media (2mL) was added to the top of each well and replaced every 4 days.       
Extracellular Flux Analyses 
Cellular bioenergetics under conditions of nutrient stress were measured using a Seahorse 
XFe96 Metabolic Analyzer (Agilent Technologies).  Panc02 Atg5+/+ and Atg5-/- cells were seeded 
in a 96-well plate (5 x 103 cells/well).  After 48 hours, culture media was removed and 100 µL of 
pre-warmed assay medium (XF base medium supplemented with 5 mM glucose, 2 mM glutamine, 
1 mM sodium pyruvate, pH 7.4) was added to each well.  The plate was incubated in a CO2-free 
chamber at 37°C for one hour.  Basal oxygen consumption rate (OCR) was measured. 
Invasion and Migration 
Matrigel invasion chambers (Corning BioCoat Matrigel Invasion Chambers, #354480) 
were used to assess invasiveness.  Matrigel invasion chambers were thawed for 30 minutes at room 
temperature and then incubated at 37°C for 2 hours in serum-free media (500 µL).  After 2 hours, 
the Matrigel Invasion Chambers were moved to a fresh plate to wells containing 500 µL of growth 
factor-supplemented media (10% FBS).  Panc02 Atg5+/+ and Atg5-/- cells were seeded in a 6-well 
plate (1 x 104 cells/well) and, after 24 hours, the culture media was replaced with serum-free media 
for an additional 24 hours.  Following serum deprivation, cells were seeded (2.5 x 104 cells/assay) 
into the top chamber of the Matrigel-containing insert.  After 18 hours, the Matrigel-containing 
insert was removed, the underside of the invasion chambers was stained with 5% CV in methanol, 
and invasive cells were counted.    
  Migration assays were also used to determine the migratory capacity of Atg5+/+ and Atg-/- 
Panc02 cells.  Cells were seeded (7.0 x 104 cells/side of insert) on both sides of an insert (Ibidi 
#170322/3).  After the cells had adhered for 24 hours, the insert was removed, and cell migration 
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was measured 12 hours after removing the insert via imaging using the EVOS FL Auto 2 Cell 
Imaging System.   
Animal Study  
All animal studies were approved by the Institutional Animal Care and Use Committee of 
the University of North Carolina at Chapel Hill.  Mice were housed in a climate-controlled 
Department of Laboratory Animal Medicine facility with a 12-hour light: dark cycle, with ad 
libitum access to water and diets as described below.  
Male C57BL/6 mice (N=80) (Charles River Labs, Frederick, MD) were acclimated for a 
week and then randomly assigned to one of two dietary regimens (n=40/diet).  Diets were obtained 
from Research Diets and dietary regimens included: ad libitum control diet (CON) (#D12450J) 
and a 30% calorie restricted diet (CR) (#D15032801) (Table 2).   
Table 2. Animal study dietary regimens 
Dietary Group Regimen  
Control (CON)  Ad libitum, 10 kcal % fat 
Calorie Restricted (CR) 30% restriction relative to CON 
 
After 10 weeks on respective diets, mice were sacrificed for intermittent endpoint tissue 
analysis (n=10/diet) or received intrapancreatic injections of Atg5+/+ or Atg5-/- Panc02 cells 
transduced with a GFP/Luciferase construct (n=15/diet + Panc02 genotype).  Weekly imaging was 
performed following an intraperitoneal injection of 200 µL D-Luciferin followed by isoflurane 
anesthesia using an IVIS Lumina II.  In accordance with humane euthanasia regulations, mice were 
euthanized at the 14-week time point using carbon dioxide inhalation and cervical dislocation.  
Tumor, pancreas, muscle, liver, and serum were collected from each mouse. 
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Results: 
I. Pharmacological Inhibition of Autophagy 
In vitro glucose restriction induces autophagy in pancreatic cancer  
 
Nutrient stress in KRAS-driven PDAC induces autophagy, a process that has been 
associated with promoting tumor growth and progression due to mobilization of metabolites used 
to provide energy (Guo, Chen et al. 2011, White 2015).  We hypothesized that pharmacological 
inhibition of autophagy under conditions of nutrient stress would induce apoptosis and impair 
colony formation of PDAC cell lines in vitro.  Under nutrient replete conditions, CQ treatment 
resulted in significantly greater LC3B II accumulation compared to vehicle treatment in MIA-
Paca-2 cells indicating the disrupted maturation of the autophagolysosome, and therefore 
inhibition of autophagy (Figure 1B; P= 0.015 a v b).  In Panc02 cells, CQ treatment, relative to 
control, resulted in moderately increased LC3B II accumulation that did not reach statistical 
significance (Figure 1A; P=0.094).        
Serum restriction and glucose deprivation were used to induce nutrient stress in vitro (Table 
1, Methods).  Under the culture conditions used, neither serum deprivation or glucose restriction 
induced autophagy as measured by LC3B II accumulation in Panc02 and MIA Paca-2 cells (Figure 
1A, 1B).  However, CQ administration in combination with glucose restriction in Panc02 cells 
resulted in significantly greater LC3B II accumulation compared to the 10% FBS control and the 
1% FBS condition (Figure 1A; P=0.039 a v b, P=0.048 a v b).  These findings suggest that CQ 
treatment effectively inhibits autophagy induced by glucose restriction.         
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Figure 1. Autophagy induced by reduced FBS or glucose can be inhibited by CQ 
Panc02 cells (A) and MIA PaCa-2 cells (B) were treated with 10 µM CQ for 48 hours and lysed.  LC3B 
protein expression was analyzed.  Representative images selected from N=3 experiments. Data presented 
as the mean + SEM.  An unpaired t-test was used for data sets containing two groups, two-way ANOVA 
with Sidak’s multiple comparison test was used for data analysis of multiple groups (P < 0.05 was 
considered statistically significant, different letters indicate significance). 
 
Autophagy inhibition in combination with growth factor reduction drastically impairs 
proliferation in pancreatic cancer cells 
In Panc02 cells, culture in low-serum conditions resulted in significant reduction in 
proliferation of approximately 50% relative to control (Figure 2A; P<0.0001 a vs b), with similar 
degree of proliferation inhibition observed under conditions of glucose restriction (Figure 2B; 
P=0.049 a vs b).  The short-term application of CQ in growth factor-replete media also 
significantly reduced Panc02 proliferation relative to control, while the application of CQ in the 
context of low serum further inhibited proliferation (Figure 2A; P<0.0001 a vs c, P<0.0001 b vs 
c).  In contrast, short-term CQ addition in the context of low glucose did not exert any additional 
inhibitory effect on Panc02 proliferation (Figure 2B).  Low serum conditions also impaired Panc02 
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colony formation, a measure of proliferation on a longer time scale, to a greater extent than low-
glucose in the absence of CQ (Figure 2C; P<0.0001 a vs c, P<0.0001 a vs d).  Remarkably, long 
term in vitro administration of CQ substantially impaired Panc02 colony formation under all 
conditions (Figure 3C; P<0.0001 a vs b).  While the effects of serum and glucose restriction on 
proliferation in MIA PaCa-2 cells were less pronounced (Figures 3D-E), chronic treatment with 
CQ again drastically impaired colony formation under all culture conditions (Figure 3F; P<0.0001 
a vs b).  These results strongly support a role for autophagy in survival of PDAC lines, and that 
autophagy induction plays a key role in cellular to nutrient stress. 
 
Figure 2. CQ and nutrient restriction synergize in PDAC growth inhibition  
Panc02 cells (A, B) and MIA PaCa-2 cells (D, E) were treated with nutrient deplete media and 10 µM CQ 
for 48 hours and an MTT assay was used to measure viability.  Additionally, Panc02 cells (C) and MIA 
PaCa-2 cells (F) were treated with nutrient deplete media and 10 µM CQ for 2 weeks with treatment media 
changed every 4 days; colonies were stained with crystal violet.  Representative images selected from N=3 
experiments. Data presented as the mean + SEM.  Two-way ANOVA with Tukey’s multiple comparison test 
was used for data analysis of multiple groups (P < 0.05 was considered statistically significant, different 
letters indicate significance). 
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II. Genetic Autophagy Deficiency 
Permanent loss of Atg5 does not impair PDAC proliferation in 2-dimensional culture 
While CQ is effective for transiently inhibiting autophagy, we hypothesized that permanent 
autophagy ablation over time may result in the development of autophagy independence in PDAC 
cells.  To investigate the effect of permanent, total autophagy inhibition on viability of PDAC 
cells, CRISPR/Cas9 was used to generate a Panc02 cell line deficient in Atg5.  Western 
immunoblot analysis revealed no detectable expression of Atg5 at 55 kDa, and the lack of LC3BII 
at 16 kDa demonstrates prevention of LC3B lipidation and therefore disruption of autophagosome 
formation (Figure 3A).  Despite autophagy deficiency in the Atg5-/- cells, no significant differences 
in short term proliferation as measured through the expression of PCNA, 96-hour growth, or MTT 
assay (Figure 3A, 3B, 3C).  In stark contrast to the results observed with chronic pharmacological 
inhibition (Figure 2C & 2F), long term clonogenic growth was also unaffected in Atg5-/- cells 
compared to Atg5+/+ cells (Figure 3D).  Thus in vitro results indicate that permanent autophagy 
inhibition in the Panc02 PDAC line does not alter growth dynamics under adherent conditions 
which indicates profound cellular reprogramming.     
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Figure 3. Atg5 knockout in Panc-02 cells does not affect growth in vitro  
Atg5+/+ and Atg5-/- cells were lysed and expression of Atg5, PCNA, and LC3B were analyzed (A).  Short 
term growth was measured counting Atg5+/+ and Atg5-/- cells over a 96-hour period (B).  Atg5+/+ and Atg5-/- 
cells were seeded and after 48 hours, an MTT assay was used to measure viability (C).  Atg5+/+ and Atg-/- 
cells were seeded and media was changed every four days; colonies were stained with crystal violet.  
Representative images selected from N=3 experiments. Data presented as the mean + SEM.  An unpaired 
t-test was used for data sets containing two groups, two-way ANOVA with Sidak’s multiple comparison test 
was used for data analysis of multiple groups (P < 0.05 was considered statistically significant, different 
letters indicate significance). 
       
Consistent with results shown in Figure 2, growth in serum restricted conditions 
significantly reduced proliferation of Atg5+/+ by more than 50% relative to control conditions 
(Figure 4A; P<0.0001 a vs b).  However, glucose restricted media did not exert any inhibitory 
effect on Atg5+/+ proliferation (Figure 4D).  In nutrient replete conditions, Atg5 knockout did not 
alter the rate of proliferation compared to wildtype cells (Figure 4A, 4D).  In contrast, under serum-
restricted conditions the proliferation of Atg5-/- was significantly impaired; notably, Atg5+/+cells 
were more sensitive to serum depletion compared to Atg5-/- cells (Figure 4A; P=0.0008 a vs c, 
P<0.0023 b vs c).  Similar to our findings with transient autophagy inhibition (Fig 2B and 2E), in 
the context of low glucose, deletion of Atg5 in PDAC did not affect cell proliferation (Figure 4D).  
In Atg5+/+ cells, low serum conditions diminished Atg5+/+ colony formation to a greater extent than 
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low glucose (Figure 4B; P=0.0008 a vs b, Figure 4E; P=0.0498 a vs b).  Importantly, 2D colony 
formation was significantly less impaired by serum deprivation and glucose restriction in Atg5-/- 
cells compared to Atg5+/+ (Figure 2B; P=0.0046, Figure 2E; 0.0498).  To analyze differential 
metabolism occurring as a result of Atg5 knockout, oxygen composition rates (OCR) were 
measured.  Neither nutrient stress nor autophagy inhibition had a significant effect on basal OCR 
(Figure 4C & F).  These results suggest that permanent autophagy ablation, as occurs with the 
Atg5 knockouts, does not further hinder growth in the context of nutrient stress, but rather that an 
adaptive response to sustained loss of autophagy exerts a protective effect in PDAC.  
 
Figure 4. Effects of exogenous nutrient stress and autophagy deficiency on cell growth and metabolism 
Atg+/+ and Atg-/- cells were treated with serum-restricted media (A) and low-glucose media (D) for 48 hours 
and an MTT assay was used to measure viability.  Additionally, Atg+/+ and Atg-/- cells were treated serum-
restricted media (B) and low-glucose media (E) for 2 weeks with treatment media changed every 4 days; 
colonies were stained with crystal violet.  Oxygen consumption was measured under serum restricted (C) 
and low glucose conditions (F).  Data presented as the mean + SEM for N=3 experiments.  Two-way 
ANOVA with Tukey’s multiple comparison test was used for data analysis of multiple groups  
(P < 0.05 was considered statistically significant, different letters indicate significance). 
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Atg5 deficiency reverses phenotypes associated with EMT and inhibits anchorage independent 
growth  
An anchorage-independent, agarose-based assay was used to monitor three-dimensional 
growth.  This assay revealed that Atg5+/+ cells form colonies more readily in 3D culture compared 
to Atg5-/- cells (Figure 5A; P<0.0001).  Anchorage-independent growth has been associated with 
increased metastatic potential of cancer cells (Lyons, Alizadeh et al. 2016).  First, we measured 
markers of epithelial-to-mesenchymal transition in Atg5+/+ and Atg5-/-.  Atg5 deletion did not 
significantly alter expression of the epithelial marker E-Cadherin, but significantly decreased the 
expression of the mesenchymal markers N-Cadherin and Snail in Atg5-/- cells (Figure 5A; P=0.033 
a v b, P=0.0017 a v b).  Additionally, Snail expression in Atg5-/- cells appears at a higher molecular 
weight, and is likely highly phosphorylated which further indicates the degradation and 
inactivation of this protein.  Furthermore, Atg5 deletion resulted in significant increases in cell 
migration, yet a significant and substantial decrease in invasiveness (Figure 5B; P=0.006, Figure 
5C; P=0.001).  Migration enables cells to translocate, while invasion refers to movement through 
the extracellular matrix (ECM).  These findings suggest that the development of autophagy 
independence influences EMT via reduced cellular plasticity through the robust selective pressure 
exerted on these cells. 
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Figure 5. Atg5 deletion induced a more epithelial-like phenotype 
Cells were grown in an agar-based assay for 2 weeks and formed 3D colonies (A).  Markers of EMT 
including N-Cadherin, E-Cadherin, and Snail were altered with Atg5 knockout and quantified (b).  Cell 
migration was significantly increased in Atg5-/- cells (C), while invasion was significantly decreased (D).  
Data presented as the mean + SEM, n=3, representative images selected.  An unpaired t-test was used for 
data analysis (P < 0.05 was considered statistically significant, different letters indicate significance)   
 
Animal Study 
 Our in vitro studies above indicated that permanent autophagy ablation interferes with 
anchorage-independent growth yet may also allow for resilience in the face of nutrient stress.  To 
determine whether our in vitro findings influenced PDAC biology in vivo, cells were transplanted 
into an animal model of caloric restriction (CR).  At the time of sacrifice, male C57BL/6 mice 
prescribed a CR diet had significantly decreased body weight compared to mice on a CON diet 
(P<0.0001).  Upon intrapancreatic injection, the complete loss of autophagy in Atg5-/- cells 
generated smaller tumors in mice prescribed a CON and CR diet compared to control Atg5+/+ cells 
(Table 2, Methods, Figure 6B; P<0.0001 a v b; P=0.044 b v c).  Additionally, the CR dietary 
regimens did not have a significant effect on tumor weight compared to the CON diet regardless 
of the Atg5 status of the cells.  While Atg5 deficiency did not affect growth in vitro, these results 
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show that cellular adaptation to loss of autophagy profoundly alters the tumorigenicity of these 
cells.   
 
Figure 6. Atg5 deficiency significantly impaired tumor formation  
Mice were prescribed a CON or CR dietary regimens for the course of the study resulting in differential 
body weights (A).  Tumor weight (B) was measured at time of sacrifice.  Data presented as the mean + 
SEM, N=15 per group.  Two-way ANOVA with Tukey’s multiple comparison test was used for data analysis 
of multiple groups (P < 0.05 was considered statistically significant, different letters indicate significance). 
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Discussion: 
This body of work characterizes the effects of transient versus permanent inhibition of 
autophagy in PDAC in combination with nutrient stress.  We first confirmed inhibition of 
autophagy in PDAC cells in response to CQ.  While transient CQ treatment did not have a 
significant effect in Panc02 cells, LC3B II accumulation was observed in MIA PaCa-2 cells, 
indicating successful inhibition of autophagy (Figure 1).  A greater number of Panc02 
experimental replicates would likely also show significant autophagy inhibition in response to CQ 
treatment.  Interestingly, while the mechanistic inhibition and induction of autophagy was not 
significant across cell lines, both transient and chronic CQ treatment and nutrient stress drastically 
reduced Panc02 and MIA PaCa-2 cell proliferation (Figure 2).  Perhaps more integrated measures 
of autophagy flux using different parameters such as a dual tag mCherry-GFP construct would 
better quantify this dynamic process (Bjørkøy, Lamark et al. 2009) and confirm the connection 
between nutrient stress, autophagy, and the observed inhibitory effect of CQ on PDAC growth in 
vitro.   
Nutrient stress was induced in vitro through serum restriction and glucose restriction.  Of 
these two stressors, serum restriction consistently had more pronounced effects on growth 
inhibition in the presence and absence of CQ.  The powerful effects of serum restriction are likely 
the result of alterations in a variety of pro-growth signaling pathways.  For example, growth factor 
restriction has previously been shown to reduce the activity of the Ras/MAPK and 
PI3K/Akt/mTOR pathways, leading to decreased expression of genes involved with proliferation 
(Jiang, Zhu et al. 2008).  In all growth conditions, and across both cell lines, the most substantial 
reduction in growth was observed with chronic CQ treatment over a two-week period, where long-
term CQ treatment nearly eliminated growth of PDAC cells (Figure 2 C & F).   
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However, a small number of colonies did survive, possibly due to drug efflux, 
desensitization, or development of autophagy independence in response to prolonged treatment 
with CQ.  Thus, we next investigated the effects of permanent autophagy inhibition in Panc02 cells 
to identify the impact of nutrient restriction in an autophagy-independent PDAC cell line.     
Permanent autophagy inhibition was analyzed through the genetic deletion of Atg5 in 
Panc02 cells.  Atg5 was selected because the protein product of Atg5 is required for formation of 
the autophagosome.  Contrary to the differential growth observed with transient autophagy 
inhibition, permanent autophagy inhibition had insignificant effects on short and long-term, two-
dimensional growth (Figure 3).  Atg5+/+ cells were also more sensitive to nutrient stress than Atg5-
/- cells (Figure 4).  Perhaps the permanent absence of autophagy in Atg5 knockout cells led to the 
upregulation of alternate metabolic pathways as compensatory mechanisms, yielding cells that 
were no longer reliant on autophagy (Ding, Chen et al. 2012).  Alternatively, Nishida et al. showed 
that macroautophagy can be induced via a separate, Atg5-independentpathway  (Nishida, Arakawa 
et al. 2009).  Additionally, nuclear factor erythroid 2 (Nrf2) signaling has been shown to be induced 
under conditions of autophagy deficiency, while proline metabolism may also be upregulated to 
provide energy in the absence of autophagy (Phang, Pandhare et al. 2008, Lau, Wang et al. 2010, 
Gurley, Ilkayeva et al. 2016).  Further investigation of autophagic flux and amino acid metabolism 
would reveal if Atg5 independent autophagy was indeed occurring in Atg5-/- cells (Nishida, 
Arakawa et al. 2009).  Studies are underway in the Hursting Lab to establish the mechanisms 
underlying the metabolic reprogramming that occurs with permanent Atg5 ablation. 
Notably, three dimensional clonogenic growth revealed stark differences in the ability of 
Atg5+/+ and Atg5-/- cells to form colonies.  Atg5+/+ cells formed colonies more readily under 
anchorage-independent conditions.  These findings were consistent with decreased expression of 
 25 
the mesenchymal markers N-Cadherin and Snail in Atg5-/- compared to Atg5+/+ cells (Figure 5).  
Interestingly, we also created Atg5 deficient lines in two additional claudin-low triple negative 
breast cancer cell lines (M-Wnt and met M-Wntlung cells), both of which showed similar 
modification in EMT markers.  To investigate the impact of the reduced expression of EMT-related 
proteins, cell migration and invasion were measured.  Cellular invasion was decreased in the 
epithelial-like, Atg5-/- cells; however, migration was increased (Figure 5).  The increased migration 
of the Atg5-/-cells may be a result of increased cell-cell interactions that facilitate migratory rates 
(Schaeffer, Somarelli et al. 2014) or differential expression of proteases involved in remodeling of 
the extracellular environment.  Integrins can detect environmental changes and relay information 
to alter cell shape, adhesion, and migration; proteases are released during invasion and can help 
remodel the ECM and facilitate movement into the stroma (Hood and Cheresh 2002, Yamaguchi 
and Condeelis 2007). Therefore, additional experiments could investigate integrin and protease 
activity in order to better understand the differences in cell migration and invasion in Atg5+/+ and 
Atg5-/- cells.   
Finally, to study the in vivo relevance of autophagy dependency under conditions of caloric 
restriction (nutrient stress), Atg5+/+ and Atg5-/- cells were used in an animal model.  Male C57BL/6 
mice were used because the Panc02 cell line was derived from the C57BL/6 mouse strain, and 
PDAC incidence is higher in men (Wang, Shi et al. 2001, Siegel, Miller et al. 2018).  In order to 
impose nutrient stress in vivo, a CR diet was prescribed and reduced caloric intake by 30% (Table 
2, Methods).  Our findings herein match those of Lashinger et al. in showing that permanent 
autophagy inhibition decreases tumor burden (Lashinger, O’Flanagan et al. 2016), as Atg5 
deficiency significantly impaired tumor formation and growth in both CON and CR conditions.  
However, the results of Lashinger et al. showed that CR in a PDAC model decreased tumor volume 
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and progression (Lashinger, O’Flanagan et al. 2016).  Our findings did not indicate any effect of 
CR on tumor size, likely because the tumors our study were much smaller than those reported by 
Lashinger et al. 
Reduced tumor growth by autophagy-deficient cells is consistent with our results from the 
anchorage independent growth assays, and suggest that Atg5-dependent autophagy plays a crucial 
role in tumor development in three dimensions (Figure 5&6).  In light of the EMT related findings, 
repeating our animal study using a highly metastatic cell line and analyzing the relative number of 
metastases would contribute to understanding the relationship between EMT and autophagy in 
vivo.       
PDAC continues to be a leading cause of cancer related deaths and remains a pressing 
public health issue (Siegel, Miller et al. 2018).  In order to improve PDAC outcomes, a more 
complete understanding of the metabolic weaknesses of PDAC cells may allow for novel 
interventions.  Autophagy inhibition has been used in isolation as an adjuvant therapy; however, 
our findings suggest that use in combination with nutrient stress may be more effective (Wolpin, 
Rubinson et al. 2014).  Additionally, we posit that prolonged transient autophagy inhibition may 
select for cells that are not reliant on autophagy.  Therefore, understanding and targeting metabolic 
differences between autophagy-independent cells and autophagy-competent cells may facilitate 
the development of more effective treatment strategies for Kras-driven pancreatic cancer. 
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